BioMarin Refocuses ROCTAVIAN® on Key Markets

 BioMarin Pharmaceutical is refocusing its ROCTAVIAN® business to concentrate on three markets: the United States, Germany, and Italy, where the medicine is approved and reimbursed as a treatment for severe hemophilia A. The company plans to reduce additional investments in development and manufacturing, aiming to reduce annual direct ROCTAVIAN expenses to around $60 million by 2025. The company has already begun operationalizing the reduction of ROCTAVIAN expenses this year, aiming to achieve $60 million in expenses by full-year 2025. The company expects ROCTAVIAN to be profitable by the end of 2025.

Alexander Hardy, President and CEO of BioMarin, believes that ROCTAVIAN is an important option for people with severe hemophilia A, offering years of bleed control after a single treatment. He is grateful to the hemophilia community, patients, and healthcare providers who participated in clinical trials and will continue to provide support and meet regulatory commitments for ongoing monitoring.